Marina Zacharia

Jun 22, 2023 | mdpi.com | Alexia Alexandraki |Kalliopi Keramida |Elisavet Papageorgiou |Marina Zacharia

Abstract: Simple SummaryCancer therapy-related cardiac dysfunction (CTRCD) has been an urgent medical issue in patients that receive breast cancer therapies including anthracycline-based chemotherapies and/or targeted anti-HER2 therapies such as trastuzumab. Traditional biomarkers used as standard of care may be useful indicators of cardiac damage but their use to predict the onset of CTRCD lacks reliability.